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INSECTICIDES-OPC AND CARBAMATES
INTRODUCTION
OPC poisions are esters of phosphoric acid and form two series of
compounds.
Organophosphorus compounds and carbamate are two groups of
cholinesterase inhibiting pesticides that commonly produce human
toxicity.
Those cholinesterase-inhibiting (anti- cholinesterase) insecticides
that contain phosphorous will be collectively termed organic phosphorus
compounds.
Those that contain the OC - ON linkage will be termed carbamates.
2REVIEW OF LITERATURE
Anticholinesterase insecticides likely kill more people each year
than acute poisoning by any other chemical.  Globally, severe
occupational, unintentional poisoning also happens where such
insecticides are used.
Organophosphorus compounds were initially developed 95
chemical warfare agents.  They were recognized after World War II.
More than 50 highly effective organophosphorus compounds are in use
presently.
In industrialized countries  access to toxic pesticides as much more
controlled.  Hence Anticholinesterose poisoining occurs less commonly.
In rural India poisoning occurs regularly and might result in
hundreds of casualities being treated by clinicians with  little experience
of this potentially lethal toxic syndrome.
World health Organisation classification of pesticides:
Class la extremely hazardous
Class lb Highly hazardous
Class li Moderately hazardous
3Class III slightly hazardous and active ingredients unlikely to present
acute hazard in normal use.
OLDER CLASSIFICATION:
Alkyl compounds include hexaethyl tetraphosphates
Tetraethyl pyrophosphate
Octamethyl pyrophosphamide
Malathion
Cystox
Dipterex
Aryl compounds include Parathion
Para-Oxon
Methyl Parathion
Chlorothion
Diazinon
4MODERN CLASSIFICATION:
Agirculture insecticides (highly toxic)
- OMPA
- TEPP-Parathion
- Phosdrin
- Didyston
Animal insecticides (Moderately toxic)
- Ronnel
- Coumephos
- Trichlorfon
House held insectices (low toxic)
- Malathion
- Diozinon
Victims are usually children, farmers and unskilled labourers.
Typically patients present following unintentional or suicidal
ingestion of anticholinesterose insectices or after working in areas
recently treated with these compounds.
5Direct dermal contact with I certain types of these insecticides may
be rapidly poisonous.
PHARMACOLOGY:
The basic formula for cholinesterase inhibiting compounds.
X represents leaving grcup
R1 u1 R2 my be aromatic cr aliphatic groups
Group 1 compounds contain a quarternary nitrogen at the X-
position and are collectively termed phosphoryl cholines.
Group 2 compounds are called flucrophosphates because they
possess a fluorine molecule as the leaving group.
Group 3 compound is a cyanide molecule or a halogen other than
fluorine.  The most well known agents in this group are cyonophosphates
such as the chemical weapon tabun.
The fourth group is the broadest and comprises various subgroups
based on the configuration of the R1 and R2 groups with majority falling
ino the category of either a dimethoxy on diethoxy compound.
Most of the insectices in use today fall into this last class.
6Direct acting up insecticides inhibit acetylehelinesterose without
being metabolized in the body.
Indirect acting or insecticides such as parathion and malathion
require partial metabolism to become para oxon and molaoxon
respectively to become active.
The organophosphates bind to a hydroxyl group at the active site of
Ach enzyme.
As the leaving group of the OP insecticide is split off by ache
stable but reversible bond results between the remaining substituted
phosphate of the orgnophosphate and Ache, effectively inactivating the
enzyme.
They act via all routes including
Transdermal
Trans conjunctival
Inholational across the gastrointestinal
and genitourinary mucosa and
through diurect injection.
7ABSORBTION, FATE AND EXCRETION
Organophosphorus compounds are well abscobed through the
mucus membrane of GIT, RS and intact skin.
Parothion is stored in the body fat and is slowly  released in th
circulation, prolonging the duration of its toxic action.
It is first metabolized into para oxon, which is the active toxic
agent and then to paranitrophenal, which is excreted through urine.
Malathion is metabolized in the liver by the esterases.  A part of
the metabolized product is exrerected in urine as phosphate.
Parathion may be retained for a period of about a week.
Malathion for a period of more than one week.
The presence of broken skin, dermatitis and higher environmental
temperatures further enhances cutoneuus absorption.
Most Ops are lipophilic and are therefore predicted to have a large
volume of distribution and to rapidly distribute into tissue and fat where
they are protected from metabolism.
8Dimethoate, methamidophos and oxydemeton methyl are the three
common ops that are not lipophilic with predicted small volumes of
distribution and high plasma concentration.
Moe lipophilic are the compounds mere likely to cause cholinergic
crisis.
9PATHOPHISIOLOGY
Acetyl choline is a neurotransmitter found at both parasympathetic
and sympathetic ganglia.
Skeletal neuromuscular junction.
Terminal junctions of post ganglionic parasympathetic nerves, post
ganglionic sympathetic glands and at some nerve endings within the
CNS.
Ach helps in transmission of impulses in the synaptic and neuro
muscular junction.
As the axon terminal is deparised, vesicles containing Ach fuse
with the nerve terminal, releasing Ach into the synapse or neuromuscular
junction.
Ach then binds to post synaptic receptors leading to activation.
Activation alters the flow of Na;k; cr on nerve cells and alters
membrane, resulting in propagation of the action potential.
Ops and Carbomates are inhibitors of carboxylic ester hydrclases
within the body including
Acetyl cholinesterase
10
Buftyl cholinesterase
Hepatic carboxylesterases
Poraoxonases
Chymotrypsin
And other non specific proteases
Organophosphates irreversibly bind to cholinesterase, causing the
phosphorylation and deactivation of acetylcholinesterase.
This results in accumulation of acetylcholine at the neural synopse
causing on initial overstimulation, followed by eventual exhaustion and
disruption of post synaptic neural transmission in the central nervous
system.
Ache is found in human nervous tissue and skeletal muscle and on
erythrocyte cell membranes.
Butryl cholinesterase is a hepatic derived protein that is found in
human plasma, liver, heart, pancreas and brain.
Inhibition of Ach is thought to account for all or majority of
clinical features.
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CLINICAL MANIFESTATION:
Clinical findings of acute toxicity from OPS derive from excessive
stimulation of muscorinic and nicotinic cholinergic receptors by Ach in
the central and autonomic nervous system and at skeletal neuro muscular
junction.
The classically described patient with severe of puisuning is one
who is unresponsive with pinpoint pupils-muscle fasciculoticans,
diaphoresis, salivation, lacrimation, urinary incontinence, diarrhea,
emesis and an odonr of gastric or solvents.
The timing of onset of symptoms varies according to the route,
degree of exposure and particularly the  OP.
The speed of onset will also be affected by the quantity ingested
and toxicity of the op.
Lipid solubility also likely affects time of OA set
Patients suffering massive ingestins can become symptomatic as
quickly a 5 minutes following ingestion.
Oxon ops are already active on exposture and patients become
symptomatic very soon after ingestion.
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Some thion OPS are very rapidly converted to axons and  can
similarly produce symptoms rapidly.
In contrast patients ingesting thions that are slowly converted to
active axons may not show symptom for hours.
Cholinergic receptors are found in both sympathetic and
parasympathetic nervous system.
Hence the effects of excessive ach on autonomic nervous system
may be variable.
Excessive muscarinic activity can be characterised by several
mnemonics including
SLUDGE - Salivation
Lacrimation
Urination
Defecation
Gastrointestinal emedies
DUMB BELS Defecation
Urinatich
13
Micsis
Brenchospasm
Branchorrhoea
Emesis
Lacrimotion
Salivation
Miosis is the most consistently enccuntered sign. Brenchorihoea
can be so prefuse that it mimics pulmenory oedema.
Cardiovascular monifeslations include mixed effect on the
autonomic nervous system (including increased sympathetic tone)
together with the consequences of induced hypoxia and
hypovolemia
Admission heart rate is usually normal with relatively few
patients expressing a tachycardia or bradycardia patients who have
received Atropine before admission may be tachycardic.
Hypotension may occur because of stimulation of vascular
receipts by excessive circulating Ach, severe volume los or
myocardial dysfunction.
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Respiratory complication of poisoning include.
(1)Direct pulmonory effect of bronchorrhoea, broncho
constrction (s) neuro muscular junction failure in diaphragm and
intercostal musle, loss of central respiratory drive.
Both  bronchorrhoea and bronchoconstrictrs respond to
adequate atrcpine therapy.  Unfortunately neither neuromuscular
junction failure nor loss of central respiratory drive respond to
Atropine and patients must be intubated a ventilated till respiratory
function returns.
Delayed syndromes:
The delayed syndromes include
(1)Neuromuscular junction dysfunction
(2)Organic phosphorus compound induced delayed neuropathy
Neuromuscular junction dysfunction:
A syndrome of delayed muscle weakness without cholinergic
features op fasciculation resulting in respiratory failure.
The syndrome is defined as occurring 24 to 96 hours after acute of
poisoining and after resolution of the cholinergic crisis.
15
Patients develop proximal muscle weakness especially of the neck
flexers and cranial nerve PALSIES and progress to respiratory failure that
may lAst for several weeks.
Consciousness is usually preserved.
Although the exact pathophysiologyof the syndrome is unknown, it
is clearly due to dysfunction of the neuro muscular junction with
respiratory failure resulting from weakness affecting the diaphragam and
intercostal muscles.
The treatment of intermediate syndrome is supportive with airway
protection and mechanical ventilation.
Pralidoxime or Atropine is not effective in the treatment of this
disorder, although patients may require these medications to control
concurrent cholinergic symptoms.
The weakness and paralysis commonly resolve in 5 to 18 days.
Organic phosphorus compound-induced delayed neuropathy.
Organophosphate induced delayed polyneurepathy is a rare
complication that usually occurs 2-3 weeks, after acute exposure.
It is a mixed sensory/motor polyneuropathy affecting long
myclinated neurons.
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It appears to result from inhibition of enzymes other than Ache
Early clinical features are muscle cramps followed by numbness
and paraesthesiac proceeding to flaccid paralysis of lower and
subsequently upper limbs.
Paralysis of lower limbs is associated and  foot drop and a high
stepping gait-progressing to paraplegia.
Paralysis of the arms lead to wrist drop.
Sensery loss may also be present but is variable.
There is no specific therapy for OPIDN.
Delayed neuropathies are not usually associated with carbamate
insecticides.
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DIAGNOSTIC TESTING:
The most appropriate laboratory tests for confirming cholinesterase
inhitition by insecticides are tests that measure.
1)Specific insecticids and active metabolites  in blologic tissues.
2)Cholinesterase ativity in  plasma or blood.
Verifying cholinesterate inhibites poisoning currently relies on
measurement of cholinesterase activity.
Although urine and serum assays or op compounds and their
metabolites are available, such testing is rarely obtainable within hours
Moreover normal ranges and toxic concentrations are not
established for most compounds.
The two cholinesterases commonly measured are
butyrylcholinesterase and red cell acetyl cholinesterase.
Blood samples for cholinesterase activity must be obtained in
appropriate blood tubes.
Tubes containing flucrides will permanently inactivate the enzyme
yielding falsely low activities and should never be used.
18
Specimens for RBC Ache are usually drawn into tubes containing a
chelating anticoagulant such a EDTA to prevent clot formation.
Buche does not require on anticoagulant and can be drawn into
tubes without chelators or anticoagulents.
ATROPINE CHALLENGE:
An atropine challenge  may be helpful in diagnosing cholinergic
poisoning in a patient who presents with findings suggestive of this
disorder but in whom no history is available to suggest exposure to an op
or carbomate insecticide.
In such individuals, a test dose of 1 mg of atropine in adolescent or
adults should produce classic antimuscorinic findings in particular
tachycardia, mydrasis and dry mucus membrane.
Conversely the persistence of cholinergic signs and symptoms after
an atropine challenge strongly suggests the presence of onlichelinesterase
poisoning.
19
DIFFERENTIAL DIAGNOSIS:
The differential diagnosis for cholinergic poisonings includes three
main categories
CHOLINESTERASE INHIBITORS
Carbamate insecticides
Carbamate medicinal
Organic phosphorus insecticides
Organic phosphorus ophthalmic medications
CHOLINOMIMETICS
Aceclidine
Bethanechol
Carbachol
Methacholine
Muscarine containing mushrooms
Pilicorpine
20
NICOTINE ALKALOIDS
Centine
Labeline
Nicotine
Normal RBC cholinesterase levels are 5300-10,000 u/s Markedly
decreased RBC cholinesterase levels are diagnostic
Depending on the RBC cholinesterase activity the levels of poisoning
have been also classified into
1.Mild poisoning-activity is 20-50 percent of baseline activity
2.Moderate poisoning-activity is 10-20 percent of baseline
3.Severe poisoning-activity is <10 percent of the baseline activity.
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MANAGEMENT/TREATMENT
1.PREHOSPITAL MEASURES
These include
Decontamination -done by removing all the clothing and
exposed areas of the body.
This can help in removing the residual
material from the skin
- Supportive care including airway centrol, oxygenation, ventilation
and seizure management
- Placement of an IV line and cardiac monitoring are indicated.
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2.HOSPITAL CARE
GASTRIC LAVAGE
Consider if patient presents within 60 minutes of ingestion.
Insert Nasogastric tube/gastric lavage tube
Attempt aspiration first, followed by 100 to 200 ml normal saline then
aspiration
Relatively contra indicated hydrocarbon ingestion
Gastric lavage with 1:5000 KMn)4 solution
Neurologically impaired: cuffed Endotracheal tube prior to lavage.
CATHARTICS
-Used only in combination with activated charcoal
-Sorbitol
-Single dose only
-Not recommended in poisonings that produce diarrhea  or those that
produce ileus.
23
ACTIVATED CHARCOAL
Used in conjunction with a  cathartic if patient presents within 60
minutes of ingestion.
Antiemetic suppository for nausea
Administered by nasogastric tube if unable to tolerate or unable to
swallow.
Protect airway if hydrocarbon containing pesticide or unknown
pesticide contents.
Activated charcoal should not be used routinely in management of
poisoned patients-charcoal appears to be most effective within 60 minutes
of ingestion and may be considered fcr use for this time period.  There is
insufficient evidence to support or deny its use beyond 60 minutes after
ingestion.
SYRUP OF IPECAC.
-not to be administered rcutinely in poisoned patients.
24
ADMINISTRATION OF SPECIFIC ANTIDOTES.
Draw red cell cholinesterase and plasma pseudocholinesterase
levels before therapy.
Do not delay treatment awaiting results
-Atropine administration
-Pralidoxime administration.
Atropine administration
Atropine is administered immediately to save life and continued till
the achievement of the state of Atropinisation which is diagnosed by
clinical manifeslation of flushing, dry mouth, papillary dilatation.
DOSE:
Adults and children> 12 years: 2 to 5 mg IV every is until
pulmonary symptoms controlled.
Children < 12 years: 0.05 to 0.01 mg 1 kg every 15 min
Pralidoxime
Prolidoxime brings about anticholinergic atropine like effects
resulting in freeing and reactivating chelinaterase enzymes by cleaving
25
phosphorylation-acetyl cholinesterase bind, it directly reads, detoxifies
organophosphate molecules.
Furosemide
It is given in a dose of 40 to 160 mg IV to alleviate the pulmonary
congestion remaining after full atropinisation.
Benzodiazepines:
If you give in a dose of 5 to 10 mg slow IV push for seizures,
repeated every 5 to 10 mm to central or maximum upto 3c mg in adults.
Lorazepam may also be used.
Complications:
Immediate complications
- Pulmonary Oedema
- Aspiration pneumonia
- Chemical pneumonitis
- Hyper/Hypoglycemia
- Transient liver function &
Coagulation abnormalities
- Death if not treated within 24 hours of
poisoning
26
Delayed complications -complications related to CNS-
Paralysis
GBS
Precautions during treatment:
Poison arising should wear gloves, muscle etc to prevent getting
persuned by absorption via skin a inhalation of poisonous fumes through
respiratory tract.
Never give the following drugs:
Morphine
Aminophylline
Thenothiazine
Reserpine.
Perform blood cholinesterase level estimation to diagnose the case or
assess prognosis with treatment.
27
AIM & OBJECTIVES
To investigate the relevance of plasma cholinesterase level to
severity of OP poisoning and to evaluate usefulness of AchE in predicting
clinical outcome.
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MATERIALS AND METHODS
PLACE OF STUDY:
Department of Internal Medicine
Stanley Medical College.
STUDY DESIGN:
Observational Study
STUDY PERIOD:
April, 2016 to September 2016
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OPERATIONAL DEFINITION:
Any person who develops muscarinic, nicotinic and CNS
symptoms after dermal, respiratory or oral exposure to organophosphorus
compounds such as chlorpyripos, dimethoate, sorin, tabun.
Muscarinio Symptoms : Salivation, lacrimation,
urination,
defecation, emesis, miosis,
bronchorrhoca.
Microtinic Symptoms : Muscle weakness,
Fasciculations
CNS Effects : Seizures, Coma,
Respiratory failure.
Confirmation of OPC poisoning is based on the measurement of
cholinesterase activity.
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INCLUSION CRITERIA:
Patients of suspected of OPC poisoning of age > 12 years.
EXCLUSION CRITERIA
1. Patients poisoned with double insecticides.
2. Multiple poisoning with other drugs such as Opicid, diazepam,
barbituarale.
3. Patients with chronic medical illness.
4. Patients on drugs such as aminophyllinc, succinyl, choline,
reserpine and phenothiozinc type transquilizers.
5. Pregnant women or those who received treatment prior to
admission in our hospital.
SAMPLE SIZE: 100
31
METHODOLOGY:
This is an observational study wherein 100 known patients of
suspected OPC poisoning were evaluated clinically by history and
examination. Treatment was commenced as soon as the patients were
attended. The patients were given stomach wash, body was and an
intravenous line was established. An intravenous bolus of atropine was
administered promptly.
The patients were assessed for respiratory failure and intubated and
connected to mechanical ventilation. Patients were given injection
atropine till signs of atropinisation. Pralidoxime infusion were given.
ABG, complete blood picture, RBS, RFT and chest X-ray were taken
Serum cholinesterase level was estimated at the time of admission in all
patients
Based on the serum cholinesterase levels, the severity of poisoning
was defined.
HUMAN SUBJECT PROTECTION:
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The full protocol along with draft questionnaire and informed
consent will be kept in institutional ethical committees and approval will
be obtained.
INFORMED CONSENT:
Consent form will be written in both English and Tamil and
consent will be obtained from the participant’s confidentiality will be
maintained.
EXPECTED BENEFITS FROM STUDY:
Serum cholinesterase levels are used to assess the severity of
poisoning and predicting the clinical outcome.
33
RESULTS AND DISCUSSIONGroups
Groups Number
Death Group 6
Survival Group 24
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Null Hypothesis
Null Hypothesis :
H0
Death group equal in effect compared to
Survival group
Alternate
Hypothesis : H1
Death group hazardous in effect compared
to Survival group
35
Data Analysis
Descriptive statistics was done for all data and were reported in terms of
mean values and percentages. Suitable statistical tests of comparison were
done. Continuous variables were analysed with the unpaired t test..
Categorical variables were analysed with the Chi-Square Test and Fisher
Exact Test. Statistical significance was taken as P < 0.05. The data was
analysed using SPSS version 16 and Microsoft Excel 2007.
36
Age
37
Age
Groups
Death
Group
Survival
Group
Death
Group
%
Survival
Group
%
≤ 20
years 0 4 0.00 16.67
21-30
years 3 8 50.00 33.33
31-40
years 0 5 0.00 20.83
41-50
years 0 0 0.00 0.00
51-60
years 3 7 50.00 29.17
Total 6 24 100 100
38
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Age Distribution Death Group Survival Group
Mean 40.33 33.13
SD 16.93 15.51
P value
Unpaired t Test
0.3253
In the death group majority belonged to 21-30 and 51-60 years age class
interval (50.00%) with a mean age of 40.33 years. In the survival group
majority belonged to 21-30 years age class interval (33.33%) with a mean
age of 33.13 years. Among the study patients, there was no statistically
significant difference in relation to age distribution between with death
group and without survival group with a p value of >0.05 as per unpaired
t test. Therefore we fail to reject the null hypothesis that there is no
difference in age distribution between the study groups.
40
Gender
41
Gender DeathGroup
Survival
Group
Death
Group
%
Survival
Group %
Female 0 5 0.00 20.83
Male 6 19 100.00 79.17
Total 6 24 100 100
P value
Fishers Exact Test
0.5526
In the death group majority belonged to male gender class interval
(100.00). In the survival group majority belonged to male gender class
interval (79.17%). Among the study patients, there was no statistically
significant difference in relation to gender status between with death
group and without survival group with a p value of >0.05 as per fishers
exact test. Therefore we fail to reject the null hypothesis that there is no
difference in gender status between the study groups.
42
Occupation
43
Occupation DeathGroup
Survival
Group
Death
Group
%
Survival
Group
%
Own
Business 1 8 16.67 33.33
Farmer 0 1 0.00 4.17
Housewife 0 6 0.00 25.00
Mechanic 1 1 16.67 4.17
Salesman 2 1 33.33 4.17
Student 2 7 33.33 29.17
Total 6 24 100 100
P value
Fishers Exact Test
0.5433
In the death group majority belonged to salesman and student occupation
class interval (33.33%). In the survival group majority belonged to own
business occupation class interval (33.33%) followed by student
(29.17%). Among the study patients, there was no statistically significant
difference in relation to occupation status between with death group and
without survival group with a p value of >0.05 as per fishers exact test.
Therefore we fail to reject the null hypothesis that there is no difference
in occupation status between the study groups.
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Peradeniya Score (Clinical severity)
45
Peradeniya
Score
(Clinical
severity)
Death
Group
Survival
Group
Death
Group
%
Survival
Group
%
Mild (0-3) 0 11 0.00 45.83
Moderate
(4-7) 0 12 0.00 50.00
Severe (8-
11) 6 1 100.00 4.17
Total 6 24 100 100
P value
Fishers Exact Test
<0.0001
In the death group majority belonged to severe category of peradaniya
score class interval (100.00%). In the survival group majority belonged to
moderate category of peradaniya score class interval (50.00%) followed
by mild category (45.83%). Among the study patients, there was a
statistically significant difference in relation to peradaniya score status
between with death group and without survival group with a p value of
<0.05 as per fishers exact test. Therefore we reject the null hypothesis
that there is no difference in occupation status between the study groups.
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Discussion
The incidence of severe category of peradaniya score was significantly
more in death group compared to survival group by a percentage
difference of 95.83%  (96% higher). This difference is significant with a
p-value of <0.0001 as per fishers exact test.
Conclusion
In this study we can safely conclude that a significantly increased severe
category of peradaniya score incidence is associated with death group
compared to increased mild category of peradaniya score incidence found
in survival group in patients admitted with organophosphorus poisoning.
In other words severe category of peradaniya score occurrence is 24 times
more common among patients who died due to organophosphorus
poisoning compared to survived patients. The increased clinical severity
in patients admitted with organophosphorus poisoning as calculated by
peradaniya score results most probably in death. Hence the scale assists in
grading severity of in patients admitted with organophosphorus poisoning
at first contact and help in predicting possible outcome.
47
Amount of Consumption
48
Amount of
Consumption
- Groups
Death
Group
Survival
Group
Death
Group
%
Survival
Group
%
≤ 50 ml 0 9 0.00 37.50
51-75 ml 1 7 16.67 29.17
76-100 ml 2 7 33.33 29.17
101-125 ml 0 1 0.00 4.17
126-150 ml 1 0 16.67 0.00
> 150 ml 2 0 33.33 0.00
Total 6 24 100 100
49
50
Amount of
Consumption
Distribution
Death Group Survival Group
Mean 131.67 65.63
SD 60.80 26.51
P value
Unpaired t Test
0.0003
In the death group majority belonged to 76-100 ml and > 150 ml OP
consumption amount class interval (33.33%) with a mean intake of
131.67 ml. In the survival group majority belonged to < 50 ml OP
consumption amount class interval (65.63%) followed by 51-75 ml and
76-100 ml class interval (29.17%) with a mean intake of 65.63 ml.
Among the study patients, there was a statistically significant difference
in relation to OP consumption amount distribution between with death
group and without survival group with a p value of <0.05 as per unpaired
t test. Therefore we reject the null hypothesis that there is no difference in
OP consumption amount distribution between the study groups.
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Discussion
The mean OP consumption amount was significantly more in death group
compared to survival group by a mean difference of 66.04 ml(50.00%
higher). This difference is significant with a p-value of 0.0003 as per
unpaired t test.
Conclusion
In this study we can safely conclude that a significantly increased mean
OP consumption amount is associated with death group compared to
survival group in patients admitted with organophosphorus poisoning.
In other words mean OP consumption amount is 2.01 times more among
patients who died due to organophosphorus poisoning compared to
survived patients. The increased mean OP consumption amount in
patients admitted with organophosphorus poisoning results most probably
in death especially if it is more than 125 ml. Hence mortality is directly
proportionate to the amount of OP substances consumed.
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Vital Parameters
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Vital Parameters PR(bpm)
SBP
(mm
Hg)
DBP
(mm
Hg)
RR
(breaths
pm)
Death
Group
Mean 76.00 106.67 70.00 18.00
SD 2.19 5.16 0.00 4.38
Survival
Group
Mean 94.13 120.42 78.33 15.92
SD 16.20 13.01 7.61 3.36
P value
Unpaired t Test
0.0117 0.0181 0.0132 0.2109
In the death group the mean pulse rate, systolic blood pressure, diastolic
blood pressure, respiratory rate and temperature was 76.00, 106.67,
70.00, 18.00 and 98.50 respectively. Similarly in survival group the mean
pulse rate, systolic blood pressure, diastolic blood pressure, respiratory
rate and temperature was 94.13, 102.42, 78.33, 15.92 and 98.79
respectively.  Among the study patients, there was a statistically
significant difference in relation to PR, SBP and DBP distribution
between with death group and without survival group with a p value of
<0.05 as per unpaired t test. Therefore we reject the null hypothesis that
there is no difference in PR, SBP and DBP distribution between the study
groups.
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Discussion
The mean PR was significantly less in death group compared to survival
group by a mean difference of 18.13 bpm (19.00% lower). This
difference is significant with a p-value of 0.0117 as per unpaired t test.
The mean SBP was significantly less in death group compared to survival
group by a mean difference of 13.75 mm Hg (11.00% lower). This
difference is significant with a p-value of 0.0181 as per unpaired t test.
The mean DBP was significantly less in death group compared to
survival group by a mean difference of 8.33 mm Hg (11.00% lower). This
difference is significant with a p-value of 0.0132 as per unpaired t test.
Conclusion
In this study we can safely conclude that a significantly decreased PR,
SBP and DBP is associated with death group compared to survival group
in patients admitted with organophosphorus poisoning.
The mean PR, SBP and DBP are 1.24, 1.13 and 1.12 times more among
patients who died due to organophosphorus poisoning compared to
survived patients. The increased mean PR, SBP and DBP serves as a risk
factor for death in patients admitted with organophosphorus poisoning.
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Type of OPC
56
Type of OPC DeathGroup
Survival
Group
Death
Group
%
Survival
Group
%
Chlorpyrifos 4 7 66.67 29.17
Dimethioate 1 2 16.67 8.33
Methyl
Parathion 1 4 16.67 16.67
Phorate 0 3 0.00 12.50
Unknown 0 8 0.00 33.33
Total 6 24 100 100
P value
Fishers Exact Test
0.0843
In the death group majority consumed chlorpyrifos (66.67%) followed by
dimethionate and methyl parathion (16.67%). In the survival group
majority consumed chlorpyrifos (29.17%) followed by methyl parathion
(16.67%). Among the study patients, there was no statistically significant
difference in relation to type of OPC consumed between with death group
and without survival group with a p value of >0.05 as per fishers exact
test. Therefore we fail to reject the null hypothesis that there is no
difference in type of OPC consumed between the study groups.
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Serum Cholinesterase
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Serum Cholinesterase Groups Death Group SurvivalGroup
Death
Group %
Survival
Group %
≤ 700 IU/L (Severe Poisoning) 6 4 100.00 16.67
701-1400 IU/L (Moderate
Poisoning) 0 10 0.00 41.67
1401-3500 IU/L (Mild
Poisoning) 0 0 0.00 0.00
> 3500 IU/L (Latent
Poisoning) 0 10 0.00 41.67
Total 6 24 100 100
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Serum Cholinesterase
Distribution
Death
Group Survival Group
Mean 336.17 2732.33
SD 164.66 2415.77
P value
Unpaired t Test
0.0235
In the death group majority belonged to ≤ 700 IU/L (severe poisoning)
serum cholinesterase level class interval (100.00%) with a mean intake of
336.17 IU/L. In the survival group majority belonged to > 3500 IU/L
(latent poisoning) serum cholinesterase level class interval (41.67%) with
a mean intake of 2732.33 IU/L. Among the study patients, there was a
statistically significant difference in relation to serum cholinesterase level
distribution between with death group and without survival group with a
p value of <0.05 as per unpaired t test. Therefore we reject the null
hypothesis that there is no difference in serum cholinesterase level
distribution between the study groups.
Discussion
The mean serum cholinesterase level was significantly less in death group
compared to survival group by a mean difference of 2396.17 IU/L
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(88.00% lower). This difference is significant with a p-value of 0.0235 as
per unpaired t test.
Conclusion
In this study we can safely conclude that a significantly decreased mean
serum cholinesterase level is associated with death group compared to
survival group in patients admitted with organophosphorus poisoning.
In other words extremely lowered mean serum cholinesterase level is 8.13
times more among patients who died due to organophosphorus poisoning
compared to survived patients. The decreased mean serum cholinesterase
level in patients admitted with organophosphorus poisoning results most
probably in death especially if it is less than ≤ 700 IU/L. Hence mortality
is inversely proportionate to the mean serum cholinesterase level
measured in the patient on admission.
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Mechanical Ventilation
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Mechanical
Ventilation
Death
Group
Survival
Group
Death
Group
%
Survival
Group
%
Mechanical
Ventilation - 0 22 0.00 91.67
Mechanical
Ventilation + 6 2 100.00 8.33
Total 6 24 100 100
P value
Fishers Exact Test
<0.0001
In the death group majority had mechanical ventilation (100.00%). In the
survival group majority had no mechanical ventilation (91.67%). Among
the study patients, there was a statistically significant difference in
relation to mechanical ventilation status between with death group and
without survival group with a p value of <0.05 as per fishers exact test.
Therefore we reject the null hypothesis that there is no difference in
mechanical ventilation status between the study groups.
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Discussion
The incidence of mechanical ventilation was significantly more in death
group compared to survival group by a percentage difference of 91.67%
(92% higher). This difference is significant with a p-value of <0.0001 as
per fishers exact test.
Conclusion
In this study we can safely conclude that a significantly increased
mechanical ventilation incidence is associated with death group compared
to survival group in patients admitted with organophosphorus poisoning.
In other words mechanical ventilation occurrence is 12 times more
common among patients who died due to organophosphorus poisoning
compared to survived patients. hence mechanical ventilation in patients
admitted with organophosphorus poisoning is a risk factor for predicting
mortality and most often results in death.
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ICU Stay Days
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ICU
Stay
Days
Groups
Death
Group
Survival
Group
Death
Group
%
Survival
Group
%
≤ 3
Days 2 18 33.33 75.00
4 to 7
days 2 5 33.33 20.83
> 7
days 2 1 33.33 4.17
Total 6 24 100 100
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ICU Stay Days
Distribution Death Group Survival Group
Mean 5.17 2.79
SD 2.79 1.93
P value
Unpaired t Test
0.0201
In the death group majority belonged to > 7 days ICU stay duration
(33.33%) with a mean stay of 5.17 days. In the survival group majority
belonged to ≤ 3 Days ICU stay duration (41.67%) with a mean stay of
2.79 days. Among the study patients, there was a statistically significant
difference in relation to ICU stay duration between with death group and
without survival group with a p value of <0.05 as per unpaired t test.
Therefore we reject the null hypothesis that there is no difference in ICU
stay duration between the study groups.
Discussion
The mean ICU stay duration was significantly more in death group
compared to survival group by a mean difference of 2.38 days (46.00%
higher). This difference is significant with a p-value of 0.0201 as per
unpaired t test.
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Conclusion
In this study we can safely conclude that a significantly increased mean
ICU stay duration is associated with death group compared to survival
group in patients admitted with organophosphorus poisoning.
In other words ICU stay duration is elevated 1.85 times more among
patients who died due to organophosphorus poisoning compared to
surviving patients. The increased mean ICU stay duration in patients
admitted with organophosphorus poisoning results most probably in death
especially if it is greater than 5 days. Hence mortality is directly
proportionate to the mean ICU stay duration.
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Serum Cholinesterase Vs ClinicalSeverity
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Serum Cholinesterase
Vs Clinical Severity Mild Moderate Severe
Mean 5090.09 782.92 315.29
SD 1422.07 267.68 160.14
P value
Single Factor ANOVA
<0.0001
When serum cholinesterase levels were matched against clinical severity,
the mild , moderate and severe category of clinical severity patients had
mean serum cholinesterase levels of 5090.09, 782.92 and 315.29 IU/L
respectively. Among the study patients, there was a statistically
significant difference in relation to serum cholinesterase levels between
clinical severity groups with a p value of <0.05 as per single factor
ANOVA test. Therefore we reject the null hypothesis that there is no
difference in serum cholinesterase levels between clinical severity
groups.
Discussion
72
The mean serum cholinesterase levels were significantly more in mild
clinical severity group compared to moderate clinical severity group  by a
mean difference of 4307.17 IU/L (85.00% higher).
The mean serum cholinesterase levels were significantly more in
moderate clinical severity group compared to severe clinical severity
group  by a mean difference of 467.63 IU/L (60.00% higher).
This difference is significant with a p-value of< 0.0001 as per single
factor ANOVA test.
Conclusion
In this study we can safely conclude that a significantly increased mean
serum cholinesterase levels is associated with mild clinical severity group
compared to significantly decreased mean serum cholinesterase levels is
associated with severe clinical severity group in patients admitted with
organophosphorus poisoning.
In other words mean serum cholinesterase levels is elevated 6.50 times
more among mild clinical severity group patients compared to severe
clinical severity group patients admitted with organophosphorus
poisoning. Hence clinical severity is inversely proportionate to the mean
serum cholinesterase levels.
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Serum Cholinesterase Vs PeradeniyaScore
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Serum Cholinesterase Vs Peradeniya Score - Correlation and Regression
Statistics
Multiple R -0.766964
R Square 0.588233
Adjusted R Square 0.573527
Standard Error 1.675812
Observations 30
Significance F <0.0001
There is a strong negative and inverse correlation between increase in
serum cholinesterase levels and corresponding decrease in peradeniya
score. This is indicated by the Pearson's R Correlation value of -
0.766964. This means as serum cholinesterase levels increases the
peradeniya score decreases. As per Pearson's R Correlation this increase
in serum cholinesterase levels due to corresponding increase in
peradeniya score happens 77% of times.
This direct negative, inverse and high correlation is significant with a p
value of <0.0001 as per analysis of variance test. The percentage change
is also explained in the scatter plot. This linear model explains all the
variability of the response data around its mean. Since R2is 0.588233,
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“the fitted regression equation explains 59% of the variation in Y"(Y= -
706.23 (perdeniya score)  + 1099).
Thus 1 score point increase in peradeniya score causes 392.77 IU/L
increase in in serum cholinesterase levels. This variation in serum
cholinesterase levels in relation to peradeniya score correlates 77% of
times and this variation is truly accounted 59% of times.
So we can conclude that elevated serum cholinesterase levels is an
independent negative, inverse and strong correlate of peradeniya score in
patients with type 2 diabetes mellitus.
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Limitations
1. Low sample size. So little space for robust statistical analysis.
2. Study population restricted to patients referred to our department
3. Selection bias may have influenced the results.
4. Poor financial support
5. Inability to use research design like  cohort study due to paucity of
time and resources
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CONCLUSION
In this study we can safely conclude that a significantly increased
severe category of peradaniya score incidence is associated with death
group compared to increased mild category of peradaniya score incidence
found in survival group in patients admitted with organophosphorus
poisoning.
In other words severe category of peradaniya score occurrence is
24 times more common among patients who died due to
organophosphorus poisoning compared to survived patients. The
increased clinical severity in patients admitted with organophosphorus
poisoning as calculated by peradaniya score results most probably in
death. Hence the scale assists in grading severity of in patients admitted
with organophosphorus poisoning at first contact and help in predicting
possible outcome.
In this study we can safely conclude that a significantly increased
mean OP consumption amount is associated with death group compared
to survival group in patients admitted with organophosphorus poisoning.
In other words mean OP consumption amount is 2.01 times more
among patients who died due to organophosphorus poisoning compared
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to survived patients. The increased mean OP consumption amount in
patients admitted with organophosphorus poisoning results most probably
in death especially if it is more than 125 ml. Hence mortality is directly
proportionate to the amount of OP substances consumed.
In this study we can safely conclude that a significantly decreased
PR, SBP and DBP is associated with death group compared to survival
group in patients admitted with organophosphorus poisoning.
The mean PR, SBP and DBP are 1.24, 1.13 and 1.12 times more
among patients who died due to organophosphorus poisoning compared
to survived patients. The increased mean PR, SBP and DBP serves as a
risk factor for death in patients admitted with organophosphorus
poisoning.
In this study we can safely conclude that a significantly decreased
mean serum cholinesterase level is associated with death group compared
to survival group in patients admitted with organophosphorus poisoning.
In other words extremely lowered mean serum cholinesterase level
is 8.13 times more among patients who died due to organophosphorus
poisoning compared to survived patients. The decreased mean serum
cholinesterase level in patients admitted with organophosphorus
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poisoning results most probably in death especially if it is less than ≤ 700
IU/L. Hence mortality is inversely proportionate to the mean serum
cholinesterase level measured in the patient on admission.
In this study we can safely conclude that a significantly increased
mechanical ventilation incidence is associated with death group compared
to survival group in patients admitted with organophosphorus poisoning.
In other words mechanical ventilation occurrence is 12 times more
common among patients who died due to organophosphorus poisoning
compared to survived patients. hence mechanical ventilation in patients
admitted with organophosphorus poisoning is a risk factor for predicting
mortality and most often results in death.
In this study we can safely conclude that a significantly increased
mean ICU stay duration is associated with death group compared to
survival group in patients admitted with organophosphorus poisoning.
In other words ICU stay duration is elevated 1.85 times more
among patients who died due to organophosphorus poisoning compared
to surviving patients. The increased mean ICU stay duration in patients
admitted with organophosphorus poisoning results most probably in death
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especially if it is greater than 5 days. Hence mortality is directly
proportionate to the mean ICU stay duration.
In this study we can safely conclude that a significantly increased
mean serum cholinesterase levels is associated with mild clinical severity
group compared to significantly decreased mean serum cholinesterase
levels is associated with severe clinical severity group in patients
admitted with organophosphorus poisoning.
In other words mean serum cholinesterase levels is elevated 6.50
times more among mild clinical severity group patients compared to
severe clinical severity group patients admitted with organophosphorus
poisoning. Hence clinical severity is inversely proportionate to the mean
serum cholinesterase levels.
 SUMMARY 
 OP Poisoning is a major public health problem in the developing world. 
Clinical manifestations following OP poisoning can be associated with the extent of 
decrease of Pche. 
 This study was undertaken to find out the relationship between OPC poisoning 
and serum cholinesterase levels 
 Cholinesterase is an enzyme which is responsible for breakdown of Acetyl 
Choline. 
 OPC compounds being anticholinesterases increases acetyl choline level in the 
synaptic cleft thereby producing clinical toxicity. 
 All patients admitted with OPC poisoning are given Atropine and Pralidoxime. 
However it was found in various studies that serum cholinesterase level does not 
correlate with total dose of Atropine and hence has no prognostic value in various 
organophosphorus poisoning.  
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PROFORMA 
 
NAME:                                             AGE:     SEX: 
ADDRESS:                                        CONTACT NO: 
OCCUPATION   :  
COMPLAINTS: 
 
PAST H/O 
DIABETES:         1. Yes          2. No  If yes specify_________ 
HYPERTENSION          1. Yes          2. No  If yes specify_________ 
CARDIAC ILLNESS          1. Yes   2. No  If yes specify_________  
 CKD                                         1.Yes         2.No   If yes specify 
PERSONAL H/O: 
 
H/O SMOKING: 
 
H/O ALCOHOL:        
1. Duration: 
2. Frequency of intake: 
3.Quantity: 
FAMILY HISTORY: 
RELEVANT CLINICAL EXAMINATION 
BP:             PR:                            RR: 
CVS:                                             RS:                           
PA: 
CNS: 
DATA OF MORBIDITY AND MORTALITY: 
 
Features Present/Absent PChe – Day 1  PChe – Day 5 
O2 Therapy with mask    
Respiratory Distress    
Ventilatory Support    
Survived    
Died    
 
PLASMA CHOLINESTERASE LEVELS: 
 
Features Present/Absent PChe – Day 1 
Latent 3,500 IU/L  
Mild Poisoning 1,401 – 3500 IU/L  
Moderate poisoning 701 – 1,400 IU/L  
Severe Poisoning <700 IU/L  
 
 
 
 
 
 
 
 
 
  
GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
 
“OPC POISONING AND SERUM CHOLINESTERASE LEVELS” AT 
GOVERNMENT STANLEY MEDICAL COLLEGE HOSPITAL, CHENNAI. 
 
Place of study:  Govt. Stanley medical college, Chennai 
 
 
I ……………………………………………. have been informed about the details of the study in my own 
language. 
I am aware that am suffering from decompensated disease of the liver and am willing to participate 
in this study where my serum sodium levels will be measured for further correlation with my health 
condition. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I agree to collect samples of blood/saliva/urine/tissue if study needs. 
I understand that I can withdraw from the study at any point of time and even then, I can receive the 
medical treatment as usual. 
I understand that I will not get any money for taking part in the study. 
I will not object if the results of this study are getting published in any medical journal, provided my 
personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would extend my full 
cooperation for this study.   
  
 
 Volunteer:       Witness: 
Name and address        Name and address  
Signature/thumb impression:     Signature/thumb impression 
Date:        Date: 
  
Investigator Signature and date 
 
 
 
 
 
 
 
 
 
 
 
 
  
GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
 
 
“OPC POISONING AND SERUM CHOLINESTERASE LEVELS” 
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நநநந. 
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ABBREVIATIONS 
Ache  - Acetyl Cholinesterase 
chE  - Cholinesterase 
BuchE - Butyryl Cholinesterase 
RBC  - Red Blood Cell 
 
 
 
 
 
 
 
  
 
